{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05533775",
            "orgStudyIdInfo": {
                "id": "CO43810"
            },
            "organization": {
                "fullName": "Hoffmann-La Roche",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma",
            "officialTitle": "A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination With Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma",
            "acronym": "iMATRIX GLO",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-to-evaluate-glofitamab-monotherapy-and-glofitamab-chemoimmunotherapy-in-pediatric-and-young-adult-participants-with-relapsed-refractory-mature-b-cell-non-hodgkin-lymphoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-11-16",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-10-15",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-10-15",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-09-06",
            "studyFirstSubmitQcDate": "2022-09-06",
            "studyFirstPostDateStruct": {
                "date": "2022-09-09",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-26",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Hoffmann-La Roche",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric and young adult participants with relapsed and refractory (R/R) mature B-cell non-Hodgkin lymphoma (B-NHL)."
        },
        "conditionsModule": {
            "conditions": [
                "Mature B-Cell Non-Hodgkin Lymphoma"
            ],
            "keywords": [
                "Relapsed",
                "Refractory",
                "Pediatrics",
                "B-NHL"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 65,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm A",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive glofitamab + R-ICE chemoimmunotherapy for up to 3 cycles (cycle length = 21 days).",
                    "interventionNames": [
                        "Drug: Obinutuzumab",
                        "Drug: Glofitamab",
                        "Drug: Rituximab",
                        "Drug: Ifosfamide",
                        "Drug: Carboplatin",
                        "Drug: Etoposide",
                        "Drug: Tocilizumab"
                    ]
                },
                {
                    "label": "Arm B",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive glofitamab monotherapy for up to 12 cycles (cycle length = 21 days).",
                    "interventionNames": [
                        "Drug: Obinutuzumab",
                        "Drug: Glofitamab",
                        "Drug: Tocilizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Obinutuzumab",
                    "description": "Participants will receive intravenous (IV) obinutuzumab pretreatment on Days 1 and 2 of Cycle 1 (Cycle length = 21 days)",
                    "armGroupLabels": [
                        "Arm A",
                        "Arm B"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Glofitamab",
                    "description": "Arm A: Participants will receive IV glofitamab on Days 8 and 15 of Cycle 1, then on Day 1 of Cycles 2 and 3\n\nArm B: Participants will receive IV glofitamab on Days 8 and 15 of Cycle 1, then on Day 1 of each cycle thereafter\n\n(Cycle length = 21 days)",
                    "armGroupLabels": [
                        "Arm A",
                        "Arm B"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Rituximab",
                    "description": "Participants will receive IV rituximab on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)",
                    "armGroupLabels": [
                        "Arm A"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Ifosfamide",
                    "description": "Participants will receive IV ifosfamide on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)",
                    "armGroupLabels": [
                        "Arm A"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Carboplatin",
                    "description": "Participants will receive IV carboplatin on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)",
                    "armGroupLabels": [
                        "Arm A"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Etoposide",
                    "description": "Participants will receive IV etoposide on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)",
                    "armGroupLabels": [
                        "Arm A"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Tocilizumab",
                    "description": "Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events",
                    "armGroupLabels": [
                        "Arm A",
                        "Arm B"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Achievement of a complete response (CR) as determined by the investigator according to the International Pediatric NHL Response Criteria for pediatric participants and Lugano Classification for young adult participants (Arm A)",
                    "timeFrame": "Up to 3 treatment cycles (cycle length = 21 days)"
                },
                {
                    "measure": "Percentage of participants with adverse events (AEs) (Arm A)",
                    "timeFrame": "Approximately 3 years"
                },
                {
                    "measure": "Serum concentration of glofitamab in combination with R-ICE chemoimmunotherapy (Arm A)",
                    "timeFrame": "Up to 3 treatment cycles (cycle length = 21 days)"
                },
                {
                    "measure": "Serum concentration of glofitamab monotherapy (Arm B)",
                    "timeFrame": "Up to 12 treatment cycles (Arm B) (cycle length = 21 days)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Objective response rate (ORR) (Arms A and B)",
                    "timeFrame": "Up to 3 (Arm A) or 12 (Arm B) treatment cycles (cycle length = 21 days)"
                },
                {
                    "measure": "Duration of complete response (DOCR) (Arm A)",
                    "timeFrame": "From the first occurrence of a documented complete response (CR) to documented disease progression or death from any cause (whichever occurs first) (approximately 3 years)"
                },
                {
                    "measure": "Progression-free survival (PFS) (Arm A)",
                    "timeFrame": "From enrollment to the first occurrence of disease progression or death from any cause (whichever occurs first) (approximately 3 years)"
                },
                {
                    "measure": "Event-free survival (EFS) (Arm A)",
                    "timeFrame": "From enrollment to the first occurrence of disease progression, death from any cause, or start of new anti-lymphoma therapy (not including planned hematopoietic stem cell transplantation (HSCT)) (approximately 3 years)"
                },
                {
                    "measure": "Overall survival (OS) (Arms A and B)",
                    "timeFrame": "From the first study treatment to the date of death from any cause (Arm A = approximately 3 years, Arm B = approximately 4 years)"
                },
                {
                    "measure": "Percentage of participants who proceed to HSCT after up to three cycles of treatment (Arm A)",
                    "timeFrame": "Up to 3 treatment cycles (cycle length = 21 days)"
                },
                {
                    "measure": "Duration of response (DOR) (Arm B)",
                    "timeFrame": "From the first occurrence of a documented CR or partial response (PR) until documented disease progression or death from any cause, whichever occurs first (approximately 4 years)"
                },
                {
                    "measure": "Percentage of participants with AEs (arm B)",
                    "timeFrame": "Approximately 3 years"
                },
                {
                    "measure": "Serum concentration of obinutuzumab (Arms A and B)",
                    "timeFrame": "Up to 3 (Arm A) or 12 (Arm B) treatment cycles (cycle length = 21 days)"
                },
                {
                    "measure": "Serum concentration of rituximab (Arm A)",
                    "timeFrame": "Up to 3 treatment cycles (cycle length = 21 days)"
                },
                {
                    "measure": "Percentage of participants with anti-drug antibodies (ADAs) (Arms A and B)",
                    "timeFrame": "Up to 3 treatment cycles (cycle length = 21 days)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age 6 months to \\< 18 years at the time of signing Informed Consent for Part 1 and Cohort B of the study, and age 6 months to \u2264 30 years old at the time of signing Informed Consent for Part 2 of the study\n* Histologically re-confirmed diagnosis, via tissue biopsy, or bone marrow aspirate, pleural effusion, or ascites, prior to study entry of aggressive mature B-NHL that expresses CD20 (reconfirmed by IHC or flow cytometry if IHC is not possible), including BL, BAL (mature B-cell leukemia FAB L3), DLBCL, and PMBCL, at the time of first R/R disease for Cohort A and second or greater R/R disease for Cohort B\n* Refractory or relapsed disease (i.e., prior treatment was ineffective or intolerable) following first-line standard-of-care chemoimmunotherapy for Cohort A and following at least two prior systemic chemoimmunotherapy regimens and who have exhausted all available established therapies for Cohort B\n* Measurable disease, defined as: At least one bi-dimensionally measurable nodal lesion, defined as \\> 1.5 cm in its longest dimension, or at least one bi dimensionally measurable extranodal lesion, defined as \\> 1.0 cm in its longest dimension; or percentage of bone marrow involvement with lymphoma cells defined by cytomorphological analysis of bone marrow aspirates\n* Adequate performance status, as assessed according to the Lansky or Karnofsky Performance Status scales: Participants \\< 16 years old: Lansky Performance Status \u2265 50%; Participants \u2265 16 years old: Karnofsky Performance Status \u2265 50%\n* Adequate bone marrow, liver, and renal function\n* Negative test results for acute or chronic hepatitis B virus (HBV), hepatitis C virus (HCV)\n* Negative HIV test at screening, with the following exception: Individuals with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy for at least 4 weeks, have a CD4 count \u2265200/uL, have an undetectable viral load, and have not had a history of opportunistic infection attributable to AIDS within the last 12 months\n* Negative SARS-CoV-2 antigen or PCR test within 7 days prior to enrollment\n* Participants and/or caregivers who are willing and able to complete clinical outcome assessments throughout the study using either paper or interviewer methods\n\nExclusion Criteria:\n\n* Isolated CNS disease of mature B-NHL without systemic involvement, and primary CNS lymphoma\n* Receipt of glofitamab prior to study enrollment\n* Ongoing adverse events from prior anti-cancer therapy that were not resolved to Grade \u2264 1 (exceptions: alopecia, Grade 2 peripheral neuropathy)\n* Grade \u2265 3 adverse events, with the exception of Grade 3 endocrinopathy managed with replacement therapy\n* Participants with active infections which are not resolved prior to Day 1 of Cycle 1\n* Prior solid organ transplantation\n* Known or suspected history of hemophagocytic lymphohistiocytosis (HLH), or chronic active Epstein-Barr viral infection (CAEBV)\n* Active autoimmune disease requiring treatment\n* History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products, except if the participant was able to safely receive it after initial administration (consider consultation with Medical Monitor)\n* History of confirmed progressive multifocal leukoencephalopathy\n* Current or past history of uncontrolled non-malignant CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease\n* Evidence of significant and uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results\n* Major surgery or significant traumatic injury \\< 28 days prior to the obinutuzumab pretreatment infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment\n* Administration of a live, attenuated vaccine within 4 weeks before the start of study treatment (obinutuzumab pretreatment) or at any time during the study treatment period and within 12 months after end of study treatment\n* Participants with any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "6 Months",
            "maximumAge": "30 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Reference Study ID Number: CO43810 https://forpatients.roche.com",
                    "role": "CONTACT",
                    "phone": "888-662-6728",
                    "email": "global-roche-genentech-trials@gene.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Trials",
                    "affiliation": "Hoffmann-LaRoche",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Children's Hospital of Alabama",
                    "status": "RECRUITING",
                    "city": "Birmingham",
                    "state": "Alabama",
                    "zip": "35233",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.52066,
                        "lon": -86.80249
                    }
                },
                {
                    "facility": "UCSF Benioff Children's Hospital Oakland",
                    "status": "RECRUITING",
                    "city": "Oakland",
                    "state": "California",
                    "zip": "94609",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.80437,
                        "lon": -122.2708
                    }
                },
                {
                    "facility": "Kaiser Permanente Oakland Medical Center",
                    "status": "RECRUITING",
                    "city": "Oakland",
                    "state": "California",
                    "zip": "94611",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.80437,
                        "lon": -122.2708
                    }
                },
                {
                    "facility": "Kaiser Permanente - Roseville",
                    "status": "RECRUITING",
                    "city": "Roseville",
                    "state": "California",
                    "zip": "95661",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.75212,
                        "lon": -121.28801
                    }
                },
                {
                    "facility": "Kaiser Permanente - Santa Clara",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Santa Clara",
                    "state": "California",
                    "zip": "95051",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.35411,
                        "lon": -121.95524
                    }
                },
                {
                    "facility": "Johns Hopkins University",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21205",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                },
                {
                    "facility": "Dana-Farber Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Childrens Mercy Hosp & Clinics",
                    "status": "RECRUITING",
                    "city": "Kansas City",
                    "state": "Missouri",
                    "zip": "64108",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.09973,
                        "lon": -94.57857
                    }
                },
                {
                    "facility": "MSKCC",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Cincinnati Children's Hospital Medical Center",
                    "status": "RECRUITING",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "45229",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                },
                {
                    "facility": "Queensland Children?s Hospital",
                    "status": "RECRUITING",
                    "city": "South Brisbane",
                    "state": "Queensland",
                    "zip": "4101",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -27.48034,
                        "lon": 153.02049
                    }
                },
                {
                    "facility": "Perth Children's Hospital",
                    "status": "RECRUITING",
                    "city": "Nedlands",
                    "state": "Western Australia",
                    "zip": "6009",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -31.98184,
                        "lon": 115.8073
                    }
                },
                {
                    "facility": "Rigshospitalet; Ny Medicin til B\u00f8rn med Kr\u00e6ft",
                    "status": "RECRUITING",
                    "city": "K\u00f8benhavn \u00d8",
                    "zip": "2100",
                    "country": "Denmark",
                    "geoPoint": {
                        "lat": 55.67594,
                        "lon": 12.56553
                    }
                },
                {
                    "facility": "H\u00f4pital Pellegrin; Service d'oncologie p\u00e9diatrique",
                    "status": "RECRUITING",
                    "city": "Bordeaux",
                    "zip": "33076",
                    "country": "France",
                    "geoPoint": {
                        "lat": 44.84044,
                        "lon": -0.5805
                    }
                },
                {
                    "facility": "Gustave Roussy",
                    "status": "RECRUITING",
                    "city": "Villejuif",
                    "zip": "94805",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.7939,
                        "lon": 2.35992
                    }
                },
                {
                    "facility": "Universitaetsklinikum Muenster; Paedriatrische Haematologie und Onkologie",
                    "status": "RECRUITING",
                    "city": "Muenster",
                    "zip": "48149",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 51.96236,
                        "lon": 7.62571
                    }
                },
                {
                    "facility": "IRCCS Ospedale Pediatrico Bambino Ges\u00f9; Clinical trial center - Pad. Salviati 1 floor",
                    "status": "RECRUITING",
                    "city": "Roma",
                    "state": "Lazio",
                    "zip": "00165",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 41.89193,
                        "lon": 12.51133
                    }
                },
                {
                    "facility": "Ospedaliera Ospedale Infantile Regina Margherita; Oncoematologia Pediatrica-Centro Trapianti Cellule",
                    "status": "RECRUITING",
                    "city": "Torino",
                    "state": "Piemonte",
                    "zip": "10126",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.07049,
                        "lon": 7.68682
                    }
                },
                {
                    "facility": "Seoul National University Hospital- Pediatric Site",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "03080",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Asan Medical Center",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "05505",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Hospital Universitari Vall d'Hebron",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08035",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Hospital Infantil Universitario Ni\u00f1o Jesus; Servicio de Onco-hematologia",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28009",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008223",
                    "term": "Lymphoma"
                },
                {
                    "id": "D000008228",
                    "term": "Lymphoma, Non-Hodgkin"
                },
                {
                    "id": "D000016393",
                    "term": "Lymphoma, B-Cell"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18828",
                    "name": "Lymphoma, B-Cell",
                    "asFound": "B-Cell Non-Hodgkin Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11222",
                    "name": "Lymphoma, Non-Hodgkin",
                    "asFound": "Non-Hodgkin Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T640",
                    "name": "B-cell Lymphoma",
                    "asFound": "B-Cell Non-Hodgkin Lymphoma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000069283",
                    "term": "Rituximab"
                },
                {
                    "id": "C000543332",
                    "term": "Obinutuzumab"
                },
                {
                    "id": "D000016190",
                    "term": "Carboplatin"
                },
                {
                    "id": "D000005047",
                    "term": "Etoposide"
                },
                {
                    "id": "D000007069",
                    "term": "Ifosfamide"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000000972",
                    "term": "Antineoplastic Agents, Phytogenic"
                },
                {
                    "id": "D000059005",
                    "term": "Topoisomerase II Inhibitors"
                },
                {
                    "id": "D000059003",
                    "term": "Topoisomerase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M18650",
                    "name": "Carboplatin",
                    "asFound": "System",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8191",
                    "name": "Etoposide",
                    "asFound": "Complete",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10117",
                    "name": "Ifosfamide",
                    "asFound": "Ventricular",
                    "relevance": "HIGH"
                },
                {
                    "id": "M373",
                    "name": "Rituximab",
                    "asFound": "Infusion",
                    "relevance": "HIGH"
                },
                {
                    "id": "M288906",
                    "name": "Obinutuzumab",
                    "asFound": "Plate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M341643",
                    "name": "Etoposide phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M230811",
                    "name": "Isophosphamide mustard",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M29348",
                    "name": "Topoisomerase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                }
            ]
        }
    },
    "hasResults": false
}